Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BCYC
Strong SellSinkerBicycle Therapeutics plc · Healthcare · United Kingdom · $294M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company pioneering a novel class of medicines called Bicycles®, which are synthetic short peptides with unique therapeutic properties. The company leverages its proprietary Bicycle® platform to develop highly selective and potent small-molecule-like biologics for oncology and other therapeutic areas. This innovative drug modality aims to address difficult-to-drug targets and improve patient outcomes.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.5M | 27.0M | 35.3M | 72.6M | 71.2% | 61.2M | 17.5M | 6.7M | -69.6% |
| EPS | -3.80 | -5.08 | -2.90 | -3.16 | — | -2.73 | -2.45 | -2.22 | — |
| Shares | 29.9M | 42.4M | 69.1M | 69.4M | +132.2% | — | — | — | — |
| Debt | 44.3M | 45.0M | 9.5M | 16.9M | -27.6% | 14.7M | — | — | — |
| Equity | 270.8M | 370.9M | 793.1M | 610.0M | 31.1% | — | — | — | — |
| Op CF | -86.1M | -60.6M | -164.7M | -249.7M | — | -206.1M | — | — | — |
| Inv CF | -19.0M | -2.9M | -1.2M | -2.4M | — | — | — | — | — |
| Fin CF | 6.7M | 250.0M | 519.8M | -0.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BCYC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BCYC | Bicycle Therapeutics plc(you) | $294M | 10 | Strong Sell |
| AVCT.L | Avacta Group Plc | $433M | 10 | Strong Sell |
| 4BB.L | 4basebio PLC | $110M | 10 | Strong Sell |
| SCLP.L | Scancell Holdings plc | $141M | 3 | Strong Sell |
| OXB.L | Oxford Biomedica plc | $859M | 14 | Strong Sell |
| TLSA | Tiziana Life Sciences Ltd | $129M | 1 | Strong Sell |
| OKYO | OKYO Pharma Limited | $88M | 4 | Strong Sell |
| AUTL | Autolus Therapeutics plc | $623M | 30 | Sell |
| SLN | Silence Therapeutics plc | $834M | 24 | Sell |
| MREO | Mereo BioPharma Group plc | $50M | 12 | Strong Sell |
Peer medians: ROE -1.8% · P/E 24.4x · Gross margin 56.8%